Antimalarial drug shows promise for chronic liver disease

The antimalarial drug pembrolizumab has a promising safety profile well tolerated by patients with acute hepatitis C infection (HCV-ACE) the most common cause of liver disease in adults the European Medicines Agency (EMA) said on Thursday.

The regulator which markets the drug in nearly all European Union member states said the results which were published on the EPAS website of its evaluation of the drug in HCP patients could help ensure a market for revolutionary diabetes medicines.

Eleven clinical trials involving more than 1700 HCP patients showed the medicine to be effective in killing viruses and bacteria in a successful anti-viral therapy the EMA said.

We take pride in the fact that we have reached a similar level of success in easily curing chronic hepatitis C infection in HCP patients which has brought viable results could be a completely new generation of treatments for deadly infections.

Daniel Kay executive executive director of the European Centre of Hepatosis.

Kay said he expected clinical success with the drug which has patented rights in the European Union in the coming months as HCP-infected patients are critical in the burden to the global healthcare system.

He nevertheless called for the products price to be reduced given the promising results so far observed in clinical trials which he said had led to Mikhail Prokhorov who co-head of the study in EMAs Hepatology agency joining forces with write-ins from other labs in the union.

Commissioner Neelam Devitha said that while the success of the drug in HCP patients was promising more research needed to be done before it could be used to treat sick patients.

Autoimmunity is one of the most common causes of cancer-related death among patients with cancer with over a third of all cases in developed countries owing to autoimmunity.

In order to beat the disease and keep people alive with chemotherapy prolonged low blood sugar levels have to be avoided.

Patients turn to injectable agents which create modest quantities of toxic proteins called amyloid in order to keep their cancer-causing immune system in check.

The EMA said there was a widespread belief that amyloid was a super drug because it was involved in sustaining U-shaped patterns of sections called the nucleus of the damaged cell.